Studies have shown that both overexpression and amplification of MET are associated with poor prognosis in patients with NSCLC, and MET amplification appears to be an independent marker of poor outcome after surgical resection of NSCLC. The gene discussed is MET; the disease is non-small cell lung carcinoma.